SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

An announcement from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals Limited announced the issuance of new unquoted equ...

Solstice Minerals Issues New Equity Securities for Employee Incentive

Solaris Resources ( ($TSE:SLS) ) has shared an announcement. Solaris Resources Inc. has released its condensed consolidated interim financial state...

Solaris Resources Reports Q3 2025 Financial Results

Solstice Minerals Limited ( ($AU:SLS) ) has shared an update. Solstice Minerals Limited announced significant growth through systematic exploration...

Solstice Minerals Limited Reports Significant Growth and Strategic Acquisitions

BMO Capital analyst Rene Cartier maintained a Buy rating on Solaris Resources yesterday and set a price target of C$14.00. The company’s shares ope...

Solaris Resources (SLSR) Receives a Buy from BMO Capital

SELLAS Life Sciences Group ( ($SLS) ) just unveiled an announcement. On October 24, 2025, SELLAS Life Sciences Group entered into a Warrant Inducem...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$1.53	+4.79%	2.97M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$1.53	+4.8%	2.97M
3
4
5
6

SLS

SLS

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel